Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% DiscountBenzinga • 06/16/21
Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & OthersPRNewsWire • 05/25/21
Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period ActivityPRNewsWire • 05/17/21
Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation ForumPRNewsWire • 04/21/21
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period ActivityPRNewsWire • 04/01/21
Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) ConferencePRNewsWire • 02/22/21
Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson's Disease and Related DisordersBusiness Wire • 02/17/21
Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical OfficerPRNewsWire • 01/04/21